Considerations for Secondary Prevention of Nutritional Deficiencies in High-Risk Groups in High-Income Countries.

Autor: Bruins MJ; DSM Nutritional Products, Wurmisweg 576, Kaiseraugst CH-4303, Switzerland. maaike.bruins@DSM.com., Bird JK; DSM Nutritional Products, Wurmisweg 576, Kaiseraugst CH-4303, Switzerland. julia.bird@DSM.com., Aebischer CP; DSM Nutritional Products, Wurmisweg 576, Kaiseraugst CH-4303, Switzerland. claude-p.aebischer@DSM.com., Eggersdorfer M; DSM Nutritional Products, Wurmisweg 576, Kaiseraugst CH-4303, Switzerland. manfred.eggersdorfer@DSM.com.
Jazyk: angličtina
Zdroj: Nutrients [Nutrients] 2018 Jan 05; Vol. 10 (1). Date of Electronic Publication: 2018 Jan 05.
DOI: 10.3390/nu10010047
Abstrakt: Surveys in high-income countries show that inadequacies and deficiencies can be common for some nutrients, particularly in vulnerable subgroups of the population. Inadequate intakes, high requirements for rapid growth and development, or age- or disease-related impairments in nutrient intake, digestion, absorption, or increased nutrient losses can lead to micronutrient deficiencies. The consequent subclinical conditions are difficult to recognize if not screened for and often go unnoticed. Nutrient deficiencies can be persistent despite primary nutrition interventions that are aimed at improving dietary intakes. Secondary prevention that targets groups at high risk of inadequacy or deficiency, such as in the primary care setting, can be a useful complementary approach to address persistent nutritional gaps. However, this strategy is often underestimated and overlooked as potentially cost-effective means to prevent future health care costs and to improve the health and quality of life of individuals. In this paper, the authors discuss key appraisal criteria to consider when evaluating the benefits and disadvantages of a secondary prevention of nutrient deficiencies through screening.
Competing Interests: The authors are employed by DSM Nutritional Products, a manufacturer of vitamins and supplier to the food, dietary supplement, and pharmaceutical industries. There were no other conflicts of interest.
Databáze: MEDLINE